[Table/Fig-2]:

Co-morbidities and laboratory parameters of patients treated in AAE and meropenem groups.

	Number of patients (n)
	AAE Group (n = 52)	Meropenem Group (n = 63)
Co-morbidities
Coronary artery disease (CAD)	12 (23.07 %)	10 (15.87 %)
Chronic obstructive pulmonary disease (COPD)	30 (57.69 %)	34 (53.96 %)
Chronic kidney disease (CKD)	13 (25.00 %)	17 (26.98 %)
Diabetes mellitus	23 (44.23 %)	26 (41.26 %)
Cerebrovascular disease	08 (15.38 %)	12 (19.47 %)
Hypertenstion	14 (26.92 %)	11 (17.46 %)
Laboratory parameters
Arterial pH <7.35	14 (26.92 %)	10 (15.87 %)
Blood urea nitrogen level >30 mg/dL (11 mmol/L)	15 (28.84 %)	19 (30.15 %)
Sodium level <130 mmol/L	19 (36.53 %)	24 (38.09 %)